Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, and Tulane University Translational Science Institute, New Orleans, LA, USA.
Department of Cardiology, First Hospital of China Medical University, Shenyang, China.
Lancet. 2023 Mar 18;401(10380):928-938. doi: 10.1016/S0140-6736(22)02603-4. Epub 2023 Mar 2.
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention on cardiovascular disease has not been established. We aimed to test the effectiveness of such an intervention compared with usual care on risk of cardiovascular disease and all-cause death among individuals with hypertension.
In this open-label, blinded-endpoint, cluster-randomised trial, we recruited individuals aged at least 40 years with an untreated systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg (≥130 mm Hg and ≥80 mm Hg for those at high risk for cardiovascular disease or if currently taking antihypertensive medication). We randomly assigned (1:1) 326 villages to a non-physician community health-care provider-led intervention or usual care, stratified by provinces, counties, and townships. In the intervention group, trained non-physician community health-care providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol to achieve a systolic blood pressure goal of less than 130 mm Hg and diastolic blood pressure goal of less than 80 mm Hg with supervision from primary care physicians. They also delivered discounted or free antihypertensive medications and health coaching for patients. The primary effectiveness outcome was a composite outcome of myocardial infarction, stroke, heart failure requiring hospitalisation, and cardiovascular disease death during the 36-month follow-up in the study participants. Safety was assessed every 6 months. This trial is registered with ClinicalTrials.gov, NCT03527719.
Between May 8 and Nov 28, 2018, we enrolled 163 villages per group with 33 995 participants. Over 36 months, the net group difference in systolic blood pressure reduction was -23·1 mm Hg (95% CI -24·4 to -21·9; p<0·0001) and in diastolic blood pressure reduction, it was -9·9 mm Hg (-10·6 to -9·3; p<0·0001). Fewer patients in the intervention group than the usual care group had a primary outcome (1·62% vs 2·40% per year; hazard ratio [HR] 0·67, 95% CI 0·61-0·73; p<0·0001). Secondary outcomes were also reduced in the intervention group: myocardial infarction (HR 0·77, 95% CI 0·60-0·98; p=0·037), stroke (0·66, 0·60-0·73; p<0·0001), heart failure (0·58, 0·42-0·81; p=0·0016), cardiovascular disease death (0·70, 0·58-0·83; p<0·0001), and all-cause death (0·85, 0·76-0·95; p=0·0037). The risk reduction of the primary outcome was consistent across subgroups of age, sex, education, antihypertensive medication use, and baseline cardiovascular disease risk. Hypotension was higher in the intervention than in the usual care group (1·75% vs 0·89%; p<0·0001).
The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death.
The Ministry of Science and Technology of China and the Science and Technology Program of Liaoning Province, China.
非医师社区卫生保健提供者主导的强化血压干预在心血管疾病方面的有效性尚未确定。我们旨在测试这种干预与常规护理相比在高血压患者的心血管疾病风险和全因死亡方面的效果。
在这项开放标签、盲终点、整群随机试验中,我们招募了年龄至少 40 岁的个体,其未治疗的收缩压至少为 140mmHg 或舒张压至少为 90mmHg(心血管疾病风险高或目前正在服用降压药物的患者为≥130mmHg 和≥80mmHg)。我们将 326 个村庄随机(1:1)分为非医师社区卫生保健提供者主导的干预组或常规护理组,按省份、县和乡镇进行分层。在干预组中,经过培训的非医师社区卫生保健提供者根据简单的逐步护理方案启动和滴定降压药物,以达到收缩压<130mmHg 和舒张压<80mmHg 的目标,并由初级保健医生进行监督。他们还为患者提供折扣或免费的降压药物和健康指导。主要有效性结果是研究参与者在 36 个月随访期间的心肌梗死、中风、需要住院的心衰和心血管疾病死亡的复合结果。每 6 个月评估一次安全性。这项试验在 ClinicalTrials.gov 注册,NCT03527719。
2018 年 5 月 8 日至 11 月 28 日,每组招募了 163 个村庄,共纳入了 33995 名参与者。在 36 个月期间,收缩压降低的净组间差异为-23.1mmHg(95%CI-24.4 至-21.9;p<0.0001),舒张压降低的差异为-9.9mmHg(-10.6 至-9.3;p<0.0001)。与常规护理组相比,干预组中发生主要结局的患者较少(每年 1.62% vs 2.40%;风险比[HR]0.67,95%CI0.61-0.73;p<0.0001)。干预组的次要结局也有所降低:心肌梗死(HR0.77,95%CI0.60-0.98;p=0.037)、中风(0.66,0.60-0.73;p<0.0001)、心衰(0.58,0.42-0.81;p=0.0016)、心血管疾病死亡(0.70,0.58-0.83;p<0.0001)和全因死亡(0.85,0.76-0.95;p=0.0037)。主要结局的风险降低在年龄、性别、教育、降压药物使用和基线心血管疾病风险的亚组中是一致的。与常规护理组相比,干预组的低血压发生率更高(1.75% vs 0.89%;p<0.0001)。
非医师社区卫生保健提供者主导的强化血压干预可有效降低心血管疾病和死亡风险。
中国科学技术部和中国辽宁省科学技术计划。